Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Elicio Therapeutics, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elicio Therapeutics, Inc. (“Elicio” or “the Company”) (NASDAQ: ELTX). Investors who purchased Elicio securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Elicio has violated federal securities laws.
Elicio Investigation Details
On June 15, 2026, Elicio announced results of its Phase 2 AMPLIFY-7P study. According to the Company, “AMPLIFY-7P did not meet the pre-specified primary endpoint of disease-free survival (“DFS”) in the intent-to-treat population.” Following this news, Elicio’s shares fell by almost 71% on the same day.
What’s Next for Elicio Investors?
If you are aware of any facts relating to this investigation or purchased Elicio securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
ELTX — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”